Streetbeat News

ZEAL

Zealand Pharma A/S.

https://www.zealandpharma.com/

CEO

Emmanuel Dulac

Employees

329

Industry

Pharmaceutical Preparation Manufacturing

Open

18.03

Mkt cap

N/A

Volume

2.2K

High

18.07

P/E Ratio

N/A

52-wk high

32.12

Low

17.47

Div yield

N/A

52-wk low

9.93

Zealand Pharma has announced its financial results for the full year 2024, including a correction with the 2024 Annual Report attached in iXBRL format.

Portfolio Pulse from

February 20, 2025 | 9:30 am

Zealand Pharma reported its 2024 financial results, highlighting significant clinical advancements in its obesity pipeline. The company secured $1.2 billion through equity raises to invest in R&D and organizational growth.

Portfolio Pulse from

February 20, 2025 | 6:15 am

Zealand Pharma announced transactions in its shares by persons with managerial responsibilities or their associates. This could indicate insider trading activity, which may affect investor sentiment.

Portfolio Pulse from

January 13, 2025 | 4:15 pm

Zealand Pharma announced transactions in its shares by persons with managerial responsibilities or their associates. This could indicate insider trading activity, which may impact investor sentiment.

Portfolio Pulse from

December 25, 2024 | 5:00 pm

Zealand Pharma announced that The Capital Group Companies, Inc. is a major shareholder. This could influence investor perception and stock performance.

Portfolio Pulse from

December 25, 2024 | 4:45 pm

The FDA has issued a Complete Response Letter to Zealand Pharma for their New Drug Application for glepaglutide, indicating that the application did not meet the necessary requirements for efficacy and safety.

Portfolio Pulse from

December 19, 2024 | 8:15 pm

Zealand Pharma has enrolled the first participant in its Phase 2b ZUPREME-1 trial for petrelintide, targeting overweight or obesity. This marks a significant step in the development of their treatment.

Portfolio Pulse from

December 10, 2024 | 2:15 pm

Zealand Pharma A/S announced its participation in the Jefferies London Healthcare Conference, which could provide exposure and networking opportunities for the company.

Portfolio Pulse from

November 13, 2024 | 5:15 pm

Zealand Pharma announced transactions in its shares by persons with managerial responsibilities or their associates.

Portfolio Pulse from

November 11, 2024 | 4:15 pm

Zealand Pharma has increased its share capital by DKK 10,110 through the exercise of employee warrants, resulting in the issuance of 10,110 new shares.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.